Cardiff Oncology Inc reports results for the quarter ended in September - Earnings Summary

Cardiff Oncology

02/11/2023 21:03

* Cardiff Oncology Inc  CRDF.OQ  reported a quarterly
adjusted
loss of 22 cents​​ per share for the quarter ended in September,
lower than the same quarter last year, when the company reported
EPS of -20 cents.  The mean expectation of four analysts for the
quarter was for a loss of 28 cents per share. Wall Street
expected results to range from -32 cents to -27 cents per share.
    * Revenue rose 51.6% to $141.00 thousand from a year ago;
analysts
expected $50.00 thousand. 
    * Cardiff Oncology Inc's reported EPS for the quarter was a
loss
of 22 cents​.
    * The company reported a quarterly loss of $9.74 million.
    * Cardiff Oncology Inc shares had fallen by 24.5% this
quarter and
lost 25.0% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 3.4%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * Wall Street's median 12-month price target for Cardiff
Oncology
Inc is $8.50 

This summary was machine generated from LSEG data November 2 at
09:02 p.m. UTC. ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2023      -0.28          -0.22          Beat
 Jun. 30 2023      -0.26          -0.25          Beat
 Mar. 31 2023      -0.23          -0.25          Missed
 Dec. 31 2022      -0.23          -0.20          Beat